From: Treatment outcome of extra-pulmonary tuberculosis in Finland: a cohort study
Variable | Total | Death | Other unfavourable | All unfavourable (death and other) together | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
N | N | OR (95% CI) | p | N | OR (95% CI) | p | N | OR (95% CI) | p | ||
Specialty responsible for starting treatment | pulmonary | 185 | 18 | 1 | 34 | 1 | 52 | 1 | |||
internal medicine | 33 | 9 | 3.50 (1.38-8.90) | 0.009 | 5 | 1.02 (0.36-2.96) | 0.96 | 14 | 0.43 (0.06-2.97) | 0.39 | |
general medicine | 2 | 2 | Inf³ | 1.00 | 0 | 1.05 | 1.00 | 2 | 0.23 (0.04-1.20) | 0.08 | |
other | 11 | 3 | 4.43 (0.98-20.14) | 0.05 | 3 | 2.35 (0.53-10.31) | 0.26 | 6 | 0.61 (0.12-2.10) | 0.37 | |
Specialty responsible for ending treatment | pulmonary | 161 | 8 | 1 | 34 | 1 | 42 | 1 | |||
internal medicine | 29 | 7 | 6.13 (1.97-19.05) | 0.002 | 5 | 1.03 (0.35-2.99) | 0.96 | 12 | 2.00 (0.88-4.53) | 0.10 | |
general medicine | 35 | 16 | 14.00 (5.21-37.65) | <0.001 | 2 | 0.41 (0.09-1.87) | 0.25 | 18 | 3.00 (1.42-6.35) | 0.004 | |
other | 6 | 1 | 3.72 (0.37-37.29) | 0.26 | 1 | 0.41 (0.09-8.09) | 0.91 | 2 | 1.42 (0.25-8.02) | 0.69 | |
Change of specialty responsible for treatment | no | 174 | 16 | 1 | 32 | 1 | 48 | 1 | |||
yes | 57 | 16 | 4.06 (1.83-9.02) | 0.001 | 10 | 1.27 (0.56-2.86) | 0.58 | 26 | 2.20 (1.19-4.09) | 0.01 | |
Number of cases per year for unit responsible for ending treatment | 1 - 4 | 55 | 16 | 4.37 (1.86-10.28) | 0.001 | 10 | 1.49 (0.63-3.50) | 0.36 | 26 | 2.51 (1.30-4.84) | 0.006 |
5 - 10 | 12 | 1 | 0.88 (0.10-7.56) | 0.91 | 2 | 0.96 (0.19-4.76) | 0.96 | 3 | 0.93 (0.24-3.64) | 0.92 | |
11 - 29 | 34 | 3 | 1.03 (0.27-3.96) | 0.96 | 8 | 1.50 (0.59-3.80) | 0.39 | 11 | 1.34 (0.59-3.03) | 0.49 | |
30 - | 129 | 12 | 1 | 22 | 1 | 34 | 1 | ||||
Treatment group | standard treatment A | 132 | 18 | 1 | 17 | 1 | 35 | 1 | |||
standard treatment B | 24 | 5 | 2.69 (0.82-8.82) | 0.10 | 9 | 5.14 (1.82-14.49) | 0.002 | 14 | 3.88 (1.58-9.53) | 0.003 | |
standard treatment C | 17 | 1 | 0.40 (0.05-3.11) | 0.37 | 2 | 0.82 (0.17-3.91) | 0.80 | 3 | 0.59 (0.16-2.19) | 0.43 | |
standard treatment D | 19 | 1 | 0.41 (0.05-3.37) | 0.41 | 5 | 2.19 (0.69-6.95) | 0.18 | 6 | 1.28 (0.45-3.62) | 0.64 | |
other combination | 34 | 6 | 1.70 (0.60-4.84) | 0.32 | 9 | 2.70 (1.05-6.96) | 0.04 | 15 | 2.19 (1.00-4.77) | 0.049 | |
ineffective | 5 | 1 | 1.35 (0.14-12.76) | 0.80 | 0 | 0 | 1.00 | 1 | 0.69 (0.07-6.41) | 0.74 | |
Change in treatment group | no | 159 | 22 | 1 | 22 | 1 | 44 | 1 | |||
yes | 72 | 10 | 1.00 (0.43-2.34) | 0.99 | 20 | 2.12 (1.05-4.27) | 0.04 | 30 | 1.56 (0.87-2.80) | 0.13 | |
Pause of treatment | no | 169 | 25 | 1 | 22 | 1 | 47 | 1 | |||
yes | 62 | 7 | 0.98 (0.39-2.45) | 0.96 | 20 | 3.17 (1.55-6.46) | 0.002 | 27 | 2.00 (1.09-3.66) | 0.02 | |
Pause during intensive phase¹ | no | 183 | 25 | 1 | 24 | 1 | 49 | 1 | |||
yes | 47 | 6 | 1.40 (0.52-3.78) | 0.51 | 18 | 4.37 (2.05-9.29) | <0.001 | 24 | 2.88 (1.43-5.78) | 0.003 | |
Pause during intensive phase, due to side effect | no | 191 | 26 | 1 | 27 | 1 | 53 | 1 | |||
yes | 40 | 6 | 1.68 (0.61-4.60) | 0.32 | 15 | 4.04 (1.82-8.92) | 0.001 | 21 | 2.85 (1.48-5.51) | 0.002 | |
Pause during continuation phase | no | 171 | 12 | 1 | 25 | 1 | 37 | 1 | |||
yes | 34 | 2 | 1.12 (0.23-5.36) | 0.89 | 12 | 3.22 (1.40-7.40) | 0.006 | 14 | 2.53 (1.17-5.50) | 0.02 | |
NA (other + ineffective) | 26 | 18 | 5 | 23 | |||||||
Total | 231 | 32 | 42 | 74 |